TNFRSF17 and Miyoshi myopathy: Additionally, after a deeper analysis, a heterozygous TNFRSF17 loss or monosomy of 16 in about 15% of MM patients never exposed to anti-BCMA therapy has been observed, letting us hypothesize a role for genomic alteration in the development of resistance to BCMA-targeting treatments [80,81].